INTRODUCTION
The production of mature megakaryocytes (MKs) from multipotent hematopoietic progenitor cells requires the coordinated activity of different cytokine signaling pathways to assure controlled cell proliferation, survival and differentiation. [1] [2] [3] Thrombopoietin (TPO) is a major hematopoietic growth factor that supports early hematopoietic cells and all the developmental stages of megakaryocytopoiesis. 4, 5 Several other cytokines can promote MK growth and platelet production in physiological or pathological circumstances, including stem cell factor, IL-1, IL-3, IL-6 and IL-11. 1,2 Increased platelet production is observed in essential thrombocytemia and during inflammation, as the inflammatory environment promotes the formation of MKs 2 . The tumor necrosis factor (TNF) family is a group of cytokines involved in the regulation of cell death, proliferation, activation and differentiation. Some members of the TNF family bind and activate death receptors, a group of surface proteins able to transduce apoptotic signals upon ligand binding. [6] [7] [8] Death receptor ligands are likely to inhibit the megakaryopoietic process, as shown by the ability of CD95 (Fas/APO-1) ligand to block megakaryocyte maturation through the specific targeting of key developmental transcription factors. 9 Recently, A Proliferation Inducing Ligand (APRIL) has been identified as a new member of the TNF family proteolytically processed in the Golgi compartment by a furin convertase and released as a soluble form. 10, 11 Furin is involved in the maturation of growth factors and integrins synthesized by MKs, and appears as a key enzyme for megakaryocytopoiesis and thrombocytopoiesis. 12, 13 APRIL mRNA levels are reportedly low in normal tissues. In contrast, high mRNA levels have been detected in tumor cell lines and in several primary tumor tissues. [14] [15] [16] Such expression has been proposed to promote cancer cell survival and proliferation, as exogenous expression of APRIL increased tumor cell growth in vitro and in vivo. 10 Although APRIL can bind to BCMA and TACI receptors, the pro-tumor effect of this cytokine seems mediated by at least one additional, yet unidentified, receptor. 15 Similarly, recent evidence supports the presence of a functional receptor, different from BCMA and TACI, in fibroblast and epithelial cell lines. 10, 15 The existence of another functional receptor is further corroborated by the inability of BLys/BAFF, another member of the TNF family capable of binding BCMA and TACI, to promote the proliferation of APRIL-sensitive tumor cells. 14, 15, 17 We speculate that the ability of APRIL to act as autocrine growth factor was not confined to tumor Platelet production was evaluated as previously described.
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APRIL and BLyS cDNAs were cloned into the retroviral vector, PINCO-GFP (green fluorescent protein). 20 CD34 + cells were subjected to six infection cycles and placed in growth medium supplemented with cycling growth factors (IL-3 100U/ml, SCF 100ng/ml, Flt3 100ng/ml) for 48 hours before sorting. GFP-positive cells were separated by flow cytometry and cultivated in serum-free medium containing 100ng/ml TPO to obtain virtually pure transduced MK populations. Protein extracts were prepared by resuspending cell pellets in 1% NP40 lysis buffer. Equal amounts of proteins were analyzed by standard immunoblot procedure. The rabbit polyclonal anti-APRIL antibody was produced as previously described, 11 and used at 5µg/ml. Anti-BLyS polyclonal rabbit antibody (BD PharMingen, Los Angeles, CA) was used at dilution of 1:1000.
RT PCR and immunoblot analysis
Cell surface binding of APRIL was assessed by incubating 2x10 5 
RESULTS AND DISCUSSION
The megakaryocytic unilineage liquid culture system recapitulates physiological megakaryocytopoiesis and allows the study of different steps of the differentiation process 18 .
In TPO-supplemented culture of cord blood CD34 + cells, morphological evaluation indicates the presence of putative mononuclear megakaryoblasts at day 2-3, then at day 10-12 cells mature in binuclear and polynucleated MKs and begin to produce platelets. 19 We analyzed megakaryocytic cells at various differentiation stages for the expression of APRIL and its receptors. Flow cytometry analysis showed that APRIL binding to its putative receptors was absent in CD34 + cells, but gradually increased during MK differentiation (Fig. 1A) . Similarly, APRIL mRNA was not present in CD34 + cells or in day 3 megakaryoblasts, but was easily detectable from day 5 until the end of the culture, reaching considerably high levels around day 9 ( Fig. 1B and C) . Moreover, immunoblot analysis revealed the presence of both full-length and soluble APRIL in MKs (Fig. 1D) . In contrast, we were not able to detect TACI or BCMA mRNA at any stage of megakaryocytic differentiation (Fig. 1B) (Fig. 2A) . Sorted cells were cultivated in MK unilineage medium for 8 days, as the previous exposure to the cycling factors during retroviral transduction reduces the time required for the complete maturation of hematopoietic precursors. 9 Megakaryocytic culture quantification revealed a significant increased expansion of APRIL-transduced cells during the proliferative phase as compared with the control populations, while during late differentiation period the differentially transduced cells showed a comparable modest increase in number (Fig. 2B) . Thus, exogenous APRIL promotes the growth of megakaryocytic cells during their expansion phase.
To determine whether the production of endogenous APRIL contributes to the megakaryopoietic process, cord blood CD34 + cells were grown in MK unilineage culture in the presence of soluble human recombinant TACI:Fc fusion protein, which binds APRIL and neutralizes its proliferative activity. As shown in Fig. 2C , exposure to TACI:Fc fusion protein dramatically reduced the growth of megakaryocytic cells, while the Fn14:Fc fusion protein that interacts with TWEAK, another member of the TNF family, was ineffective. Similarly, the addition of TACI:Fc fusion protein in the culture medium from day 5 resulted in a significant decrease of platelet production (Fig.2D) , confirming the contribution of autocrine APRIL production to megakaryocytopoiesis. Upon exposure to TACI:Fc, we did not observe a significant increase in apoptosis, nor a decreased production of platelets per single megakaryocyte (results not shown). Thus, the contribution of APRIL on megakaryocytopoiesis seems to be the result of a direct increase in MK proliferation.
Data presented here indicate that APRIL acts as an autocrine growth factor for megakaryocytic cells. During in vitro differentiation, APRIL is expressed from the promegakaryocytic stage until terminal maturation. The strong reductions of MK growth and platelet production obtained after neutralization of endogenous activity suggest that APRIL may promote the physiological megakaryocytopoiesis.
Although original reports have focused their attention on the role of APRIL in tumorigenesis, APRIL expression has been found in monocytes and dendritic cells. 21, 22 Moreover, recent data indicate that APRIL modulates B and T cell immunity, 14, 22, 23 24 Moreover, we have recently shown that autocrineparacrine VEGF loops can increase MK polyploidization through the stimulation of Flt1 receptor. 25 The ability of endogenous APRIL to contribute to MK expansion suggests that it can constitute a major autocrine growth factor for megakaryocytopoiesis. Thus, it is likely that the activity of self-produced cytokines is not restricted to the accomplishment of the MK differentiation program, but may play a considerable role in MK growth, eventually contributing to determine the amount of platelet production.
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